Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Across health care, clinicians are increasingly using patient-reported outcome measures (PROMs) to give a voice to patients and to help standardize the assessment of patients for comparison purposes. With this increasing use, the limitations of these PROMs should not be underestimated within the diverse population that we treat.
Androgen deprivation therapy potentiates cardiovascular morbidity and mortality, which is the most common cause of non-cancer-related death in patients with prostate cancer. Whether the mode of testosterone suppression affects the risk of cardiovascular adverse events is unclear, especially as the 2021 PRONOUNCE trial — which aimed to compare the cardiovascular risks of gonadotropin-releasing hormone (GnRH) antagonists with GnRH agonists — was prematurely terminated.
PSA dynamics and conventional imaging methods currently used to assess biochemical recurrence of prostate cancer after definitive treatment with radiotherapy are insufficient, especially considering that different salvage options are available. Prostate-specific membrane antigen positron emission tomography (PSMA-PET) is a novel imaging method that was shown to be more accurate than conventional imaging in prostate cancer staging, and can have a role in detecting disease recurrence after radiotherapy.
In this Review, the authors analyse all the steps of the multiparametric MRI-guided prostate cancer diagnostic pathway, focusing on quality assurance systems to minimize variation in performance and discussing quality control measures to assess and mitigate poor quality throughout the process.
In this Review, the authors discuss the novel concept of the prognostic role of prostate-specific membrane antigen (PSMA)–PET across all prostate cancer disease states in the context of established prognostic tools and describe the future directions of research on the prognostic value of PSMA–PET.
Altered lipid metabolism is a visually obvious, distinguishing feature of clear-cell renal cell carcinoma. In this Perspective the authors describe the molecular mechanisms driving fatty acid accumulation and discuss potential therapeutic targets in this disease.
